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The yellow fever virus 17D vaccine strain is one of the most effective and safe vaccines available. The immune response
after immunization is characterized by long-lasting high titers of neutralizing antibodies. Here, we have initiated a charac-
terization of YFV-17D-specific cellular immune responses. This study makes three points. First, we have identified two CD8
T cell epitopes and one CD4 T cell epitope. An H-2Kb-restricted dominant epitope was mapped in the NS3 protein, whereas
the viral envelope protein harbored an H-2Db-restricted subdominant epitope and the I-Ab-restricted CD4 T cell epitope.
Second, illustrating the concept of immunodomination, we found that after abrogation of the dominant response in H-2Kb
knockout mice, the frequencies of T cells recognizing the subdominant Db-restricted epitope increased dramatically. Finally,
the H-2Db-restricted epitope lacks the canonical Asn anchor residue at position 5, indicating that epitopes may be missed
bINTRODUCTION
The yellow fever virus (YFV) 17D vaccine strain is one
of the most effective and safe vaccines available (Barrett,
1997). Immunization with the 17D vaccine strain induces
a long-term neutralizing antibody response and provides
excellent protection against infection with virulent YFV
(Monath and Heinz, 1996; Monath et al., 2000). These
characteristics have triggered the development of live
carrier vaccines based on the YFV-17D genome. Chi-
meric YFV-17D viruses have been created by exchanging
the premembrane (prM) and envelope (E) genes from
YFV-17D by those from other flaviviruses. For example,
recombinant viruses have been developed that contain
the prM and E genes from Japanese encephalitis virus
(JEV) (Chambers et al., 1999) or dengue virus (Guirakhoo
et al., 1999, 2000; van der Most et al., 2000) in a YFV-17D
genetic background. Immunization and challenge exper-
iments in mice (Guirakhoo et al., 1999; van der Most et
al., 2000) and in monkeys (Guirakhoo et al., 2000; Monath
et al., 2000) showed that these chimeric viruses are
highly immunogenic and provide strong protective immu-
nity. The likely next step in flavivirus-based vaccine de-
velopment will be to construct recombinant flaviviruses
expressing genes or epitopes from other, unrelated
pathogens (Varnavski and Khromykh, 1999) or from tumor
antigens (McAllister et al., 2000). In fact, it has now been
1 To whom correspondence and reprint requests should be ad-
dressed at current address: Department of Immunology, Faculty of117demonstrated that Kunjin virus (a flavivirus related to JEV)
can be engineered to express a variety of genes, includ-
ing the core and NS3 genes from hepatitis C virus and
the glycoprotein G gene from vesicular stomatitis virus
(Varnavski and Khromykh, 1999).
The excellent safety record and proven efficacy of the
17D vaccine strain makes YFV-17D the obvious candi-
date for such vaccine developments. Unfortunately, how-
ever, very little is known about the antiviral immune
responses induced by this virus. Although it has been
recognized that the 17D vaccine induces long-lasting
antibody responses, the immunological basis of this is
unclear. For instance, very few data exist on the nature
and magnitude of antiviral T cell responses (Reinhardt et
al., 1998), and no T cell epitopes have been identified in
either mice or humans. Here, we have begun investigat-
ing murine YFV-17D-specific T cell responses. The incen-
tives for this were the investigation of antivector immu-
nity in YFV-based vaccines and the fact that mice have
long been used as a model for flavivirus-induced en-
cephalitis (Liu and Chambers, 2001; Schlesinger et al.,
1996), in which cellular immune responses most likely
play a key role (Marten et al., 2001; Hawke et al., 1998;
Stevenson et al., 1997). As a necessary prelude to a more
detailed analysis of YFV-specific T cell responses, we
have started to quantitate the total antiviral response and
to map T cell epitopes. The present study reports the
identification of two YFV-17D CD8 T cell epitopes and
one CD4 epitope.
Flavivirus T cell epitopes have been mapped previ-by strict application of the H-2D -binding motif. Identificat
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1996) (dengue virus, Japanese encephalitis virus, and
Murray Valley encephalitis virus), and in humans (by
analyzing the specificity of virus-specific T cell clones)
(Mathew et al., 1996; Okamoto et al., 1998; Kurane et al.,
1995, 1998; Zeng et al., 1996; Gagnon et al., 1996; Zivny et
al., 1995). The disadvantage of using T cell clones for
epitope mapping is that it does not provide quantitative
data on the antiviral response. Our strategy to map YFV
T cell epitopes is based on the direct ex vivo stimulation
of splenocytes with antigen, followed by intracellular
cytokine staining and flow cytometry (Kern et al., 1999).
As the source of antigenic stimulation we have used
syngeneic YFV-infected cells as well as a set of overlap-
ping peptides encompassing the prM and E proteins and
the nonstructural protein 3 (NS3). The major advantage
of using overlapping peptides (compared to, for example,
MHC class I motif fitting peptides (Rammensee et al.,
1995)) is that it should allow us to find both MHC class I
and class II-restricted epitopes, independent of specific
alleles. This strategy of epitope mapping by flow cytom-
etry has been successfully used to map human cytomeg-
alovirus CD8 T cell epitopes (Kern et al., 1998, 1999;
Maecker et al., 2001).
RESULTS AND DISCUSSION
To identify YFV-17D epitopes, we have focused on the
viral prM, E, and NS3 proteins. These proteins were
chosen because they appear to be the dominant targets
in human and murine T cell responses against dengue
virus (Rothman et al., 1996; Zivny et al., 1995; Mathew et
al., 1996; Brinton et al., 1998). To cover the prM, E, and
NS3 proteins, we obtained a library of overlapping 15-
mer peptides (5 amino acid overlap). As illustrated in Fig.
1, these peptides were pooled such that every peptide
was present in two pools, similar to the peptide pools
described by Kern and co-workers (Kern et al., 1998,
1999).
We first obtained an estimate of the magnitude of the
total antiviral T cell response by stimulating splenocytes
from YFV-17D-infected C57BL/6/J mice (106 PFU, sc) with
YFV-17D-infected syngeneic IC21 cells. IC21 cells are
permissive for YFV-17D infection: all cells were infected
at 48 h postinfection as assessed by immunofluores-
cence staining (data not shown). Stimulating splenocytes
with virus-infected antigen-presenting cells can provide
an accurate estimate of the total response, as shown in
our laboratory by Harrington and co-workers (Harrington
et al., 2002) in mice infected with lymphocytic choriomen-
ingitis virus. In our YFV-17D infection model, we have
analyzed both the primary (8 days postinfection) and
secondary (5 days after the secondary infection) re-
sponses. Splenocytes were harvested from infected
mice and stimulated with YFV-17D-infected IC21 cells.
The cells were incubated for 6 h in the presence of
brefeldin A and were subsequently stained with mono-
clonal antibodies against CD4 and CD8. Following per-
meabilization, the cells were stained with a monoclonal
antibody against interferon- (IFN-), and cells respond-
ing to antigenic stimulation were quantitated by flow
cytometry. We found that after the primary infection, 0.8%
of the CD8 T cells responded to epitopes presented by
YFV-17D-infected IC21 cells (Fig. 2A). This number in-
creased to 5.1% at 5 days after the secondary infection
(Fig. 2B). Based on these results, we choose to use
splenocytes from the secondary response for epitope
mapping.
To map T cell epitopes, mice were immunized with
YFV-17D (106 PFU, sc), and received a booster immuni-
zation (106 PFU, sc) 4 weeks after the first immunization.
Splenocytes were harvested at 5 days after the second
infection and were stimulated with the peptide pools.
Positive CD8 T cell responses were found after stimula-
tion with pools 7, 10, 14, and 20 (Fig. 3 and data not
shown). Responses to pools 7 and 14 were similar: 0.4
FIG. 1. Schematic representation of the organization of the peptide pools. In this arrangement, each peptide is present in two pools (Kern et al.,
1999).
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and 0.3% of CD8 T cells responded to an epitope in each
pool, respectively (Fig. 3 and data not shown). This im-
plies that peptide 19 (which is the unique peptide present
in both pools) encompassed the actual epitope (amino
acid residues 1–15 from the YFV-17D envelope protein,
AHCIGITDRDFIEGV). Similarly, 6–7% of CD8 T cells re-
sponded an epitope present in pools 10 and 20, and we
therefore concluded that peptide 94 (which is uniquely
present in both pools) comprised the epitope (residues
261–275 from the viral NS3 protein, VIDAMCHATL-
TYRML). This was confirmed by directly stimulating
splenocytes with these peptides (Fig. 5, upper panel).
Finally, we found CD4 T cell responses (0.3% of CD4 T
cells) after stimulation with pools 6 and 16 (Fig. 4), im-
plying that peptide 42 (residues 231–247 from the enve-
lope protein, LVEFEPPHAATIRVL) comprised an I-Ab-re-
stricted CD4 T cell epitope, which was indeed the case
(Fig. 4).
To determine the MHC class I restriction of the two
CD8 T cell epitopes, we infected H-2Db and H-2Kb knock-
out mice with YFV-17D, using the same protocol as
described above, and stimulated secondary splenocytes
with peptides E-1 and NS3–261. Stimulation with peptide
E-1 failed to yield a response in H2-Db knockout mice
(Fig. 5, middle panel), whereas peptide NS3–261 did not
stimulate any CD8 T cells in H2-Kb knockout mice (Fig. 5,
lower panel), identifying the epitopes in peptides E-1 and
NS3–261 as H2-Db- and H2-Kb-restricted, respectively.
Peptide NS3–261 contained a single H2-Kb motif-fitting
peptide (ATLTYRML, residues 268–275 from NS3) (Falk,
1991). Stimulation of splenocytes from YFV-17D-infected
mice confirmed that this octamer represented the Kb-
restricted epitope: 4.5% of CD8 T cells recognized the
peptide (Fig. 6). Peptide E-1 did not contain any peptide
carrying the canonical motif for H2-Db-restricted
epitopes (N on position 5 and M or I at the C-terminus)
(Falk, 1991). However, a computerized search for poten-
tial H2-Db-binding peptides, using the SYFPEITHI data-
base (Rammensee et al., 1999), identified the nonamer
IGITDRDFI (residues 4–12 from the E protein) as a po-
tential H2-Db binder, and we found that this peptide did
in fact represent the epitope (Fig. 6). The optimal 9-mer
epitope is clearly more efficient in stimulating T cells
than the 15-mer peptide E-1 (compare Figs. 3, 5, and 6).
It is of interest that this epitope carries an Asp residue at
the critical anchor position (position 5) instead of the
FIG. 2. YFV-specific CD8 T cell responses after primary and secondary immunizations. To measure YFV-specific responses, splenocytes were
harvested from YFV-17D-infected mice and were stimulated with YFV-17D infected (right panels) or uninfected (left panels) cells, and were visualized
by intracellular IFN- staining. Splenocytes were harvested 8 days after primary YFV-17D immunization (A) or 5 days after the booster immunization
(B). The percentage of IFN- producing CD8 T cells is indicated in the top right corner of each plot.
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canonical Asn. Although non-motif-fitting epitopes have
been described before (Borson et al., 1997; Sadovnikova
et al., 1994), the presence of an Asp residue at the H-2Db
anchor position is novel. When Falk and co-workers
originally defined the H2-Db-binding motif by pool se-
quencing of eluted peptides they found a weak signal for
Asp at position 5, which they attributed to hydrolysis
during the sequencing procedure (Falk et al., 1991). Our
result suggests that Asp may in fact serve as an alter-
native anchor residue for H2-Db-binding peptides. The
NS3–268 epitope was clearly dominant in both C57BL/
6/J/ mice and H2-Db knockout mice. Strikingly, more
FIG. 3. Identification of epitopes in pools 14 and 20. Splenocytes were harvested from infected mice at 5 days after the second YFV-17D
immunization and stimulated with the peptide pools indicated in Fig. 1. Epitope-specific T cell responses were visualized by intracellular IFN-
staining and the percentage of IFN- producing CD8 T cells is indicated in the top right corner of each plot.
FIG. 4. Identification of a CD4 T cell epitope in pools 6 and 16. Splenocytes were harvested from infected mice at 5 days after secondary YFV-17D
immunization and stimulated with peptide pools 6 and 16, or with peptide 42. Epitope-specific T cell responses were visualized by intracellular IFN-
staining and the percentage of IFN- producing CD4 T cells is indicated in the top right corner of each plot. The CD4 IFN- responses in the plots
are also CD8.
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then 10% of CD8 T cells responded to this single epitope
in H2-Db knockout mice (Fig. 5). The major role of NS3 as
an antigenic target in YFV-17D-infected mice is reminis-
cent of the presence of CD8 T cell epitopes in the NS3
proteins of dengue virus and Murray Valley encephalitis
virus (Rothman et al., 1996; Lobigs et al., 1994; Hill et al.,
1992). Removal of the dominant YFV NS3–268 epitope
from the antiviral response, in H2-Kb knockout mice,
resulted in a more than 7-fold increase in the numbers of
CD8 T cells recognizing the E-4 epitope (Fig. 5, and data
not shown). This provides a clear illustration of the con-
cept of immunodomination: subdominant responses are
enhanced in the absence of the dominant response
(Yewdell and Bennink, 1999). This indicates that sub-
dominance is not an intrinsic issue, but is dependent on
the presence of other epitopes. This has obvious conse-
quences in outbred populations: epitopes that are dom-
inant in one individual may be subdominant or cryptic in
other individuals with different haplotypes (Betts et al.,
2000).
FIG. 5. Peptide 19 is an H-2Db-restricted epitope from the E protein and peptide 94 (NS3) is H-2Kb restricted. Splenocytes were harvested from
infected knockout mice (Db/ and Kb/) and / mice at 5 days after the second YFV-17D immunization and stimulated with the peptides 19 and
94. T cell responses were visualized by intracellular IFN- staining and the percentage of IFN- producing CD8 T cells is indicated in the top right
corner of each plot.
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It has recently been described that CD8 T cells rec-
ognizing an epitope in the MVE NS3 protein exhibit
marked cross-reactivity: it was shown that disparate
epitopes from related flaviviruses were recognized, but
that more similar self-epitopes were ignored (Regner et
al., 2001). However, it seems unlikely that the YFV NS3
epitope that we identified here would also elicit such
cross-reactive cells, since the corresponding sequences
in other flaviviruses lack the essential Kb-anchor resi-
dues (Rammensee et al., 1995).
Our T cell epitopes will facilitate a further study of
murine T cell responses against YFV-17D. Mice have
mostly been used to study YFV-induced encephalitis (Liu
and Chambers, 2001; Schlesinger et al., 1996), and our
epitopes will now allow a detailed analysis of T cell
responses in the central nervous system. In this context,
it is interesting to note that we found strong and long-
lasting CD8 T cell responses in the brains of dengue
virus-infected mice (van der Most, Murali-Krishna, and
Ahmed, manuscript submitted). In addition, the epitopes
described here can be used to measure T cell responses
against expression vectors that are based on the YFV-
17D genome (McAllister et al., 2000). Finally, our finding
that strong, YFV-17D specific T cell responses can be
detected in mice will be helpful for mapping human CD8
T cell epitopes using HLA-A2 transgenic mice (Gianfrani
et al., 2000): we have established infection conditions
and any additional epitopes mapped in these mice
should be HLA-A2 restricted. Preliminary studies sug-
gest that at least three HLA-A2-restricted epitopes can
be identified in transgenic mice (unpublished results).
MATERIALS AND METHODS
Mice and viruses
Five-week-old female C57BL/6 mice were purchased
from The Jackson Laboratory (Bar Harbor, ME). H-2Db
and H-2Kb knockout mice (Perarnau et al., 1999) were
bred in our colony. YFV-17D virus stocks were prepared
by transfection of RNA transcripts made from the full-
length cDNA clone (Rice et al., 1989). The virus was
propagated in SW-13 cells (Leibovitz, 1973), which were
grown in minimal essential medium supplemented with
fetal calf serum, antibiotics, and L-glutamine. The mac-
rophage-like IC-21 cells (Mauel and Defendi, 1971) were
propagated in RPMI medium supplemented with fetal
calf serum, antibiotics, and L-glutamine. Mice were in-
fected by subcutaneous inoculation (at the base of the
tail) of 106 PFU YFV-17D in 50 l PBS. Secondary infec-
tions were done 3–4 weeks later.
Peptides
The library of overlapping peptides was purchased
from Chiron Mimotopes. Peptides were designed as 15-
mers, overlapping by 5 amino acids; e.g., the first NS3
peptide is SGDVLWDIPTPKIIE, and the second is PKI-
IEECEHLEDGI, etc. (Rice et al., 1985). Peptides were
arranged in pools as described by Kern and co-workers
(1999) (Fig. 1). Briefly, every peptide was present in two
pools, allowing rapid identification of the positive pep-
tide. Peptides E4-12 and NS3268-275 were synthesized
at the Department of Microbiology and Immunology at
Emory University. Single peptides were used at a con-
centration of 0.1 g/ml and peptide pools were used at a
total peptide concentration on 1.2 g/ml, i.e., 0.1 g/ml
for each individual peptide.
Intracellular cytokine staining
Splenocytes were either stimulated with peptide or
with YFV-17D-infected IC-21 cells. For peptide stimula-
tion, splenocytes (106) were incubated with peptide for
6 h, in the presence of brefeldin A. When virus-infected
IC-21 cells were used for stimulation, these cells were
first infected with YFV-17D at a multiplicity of infection of
1 and were used at 48 h postinfection. Splenocytes (8 
FIG. 6. Fine mapping of the two CD8 T cell epitopes. Splenocytes were harvested from infected mice at 5 days after the second YFV-17D
immunization and stimulated with peptides E-4 (E protein, residues 4–12, IGITDRDFI) and NS3–268 (NS3, residues 268–275, ATLTYRML). T cell
responses were visualized by intracellular IFN- staining and the percentage of IFN- producing CD8 T cells is indicated in the top right corner of
each plot.
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105) were incubated with infected or uninfected IC-21
cells (2  105) in the presence of brefeldin A. Stimulated
splenocytes were stained with monoclonal antibodies
against CD4 (FITC-labeled clone GK1.5, or PerCP-labeled
clone RM4-5, PharMingen), CD8 (R-PE or APC-conju-
gated clone 53-6.7, PharMingen), CD44 (R-PE-labeled
clone Pgp-1, PharMingen), and (after permeabilization)
interferon- (FITC- or APC-conjugated clone XMG1.2,
PharMingen). Samples were analyzed using a Becton-
Dickinson FACScalibur flow cytometer.
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